Bluepharma
BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. is a Portuguese sociedade anonima incorporated on 1 February 2001 and registered with the NIPC (tax and company registration number) 505282801 at the Coimbra Commercial Registry Office. The company’s registered address is Rua da Bayer, Edificio Bluepharma, Sao Martinho do Bispo, 3045-016 Coimbra, Portugal. As of the most recent registry data reviewed, its status is listed as active.
BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. manufactures pharmaceutical products, classified under CAE code 21201 (Fabricacao de medicamentos). It develops, produces and supplies generic and branded solid oral dosage forms and other pharmaceutical products, and became the first Portuguese pharmaceutical manufacturer to receive US FDA approval for a solid-dosage production line, in 2009, enabling exports to the United States market. The company operates as the industrial manufacturing entity within Grupo Bluepharma, a Portuguese pharmaceutical group whose activities span research, generics commercialisation and specialty pharmaceutical services, with a presence extending to Spain, Angola, Mozambique and the United States.
According to Portuguese business-registry data, BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. reported annual revenue above EUR 50 million and employed between 501 and 1,000 people, with financial statements on record for the 2023, 2024 and 2025 financial years. Its share capital is recorded at approximately EUR 5,244,940. The company is not listed on any stock exchange.
BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. is a distinct legal entity from Bluepharma Genericos – Comercio de Medicamentos, S.A. (NIPC 506037169) and Bluepharma SGPS, S.A. (NIPC 505282950), which are separate companies registered under the same Bluepharma group name.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Bluepharma – Industria Farmaceutica, S.A.
Portuguese business registries do not publish a complete, itemised shareholder register for BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. Public reporting confirms that in December 2023 the investment firm C2 Capital acquired a minority equity stake in the company through a reported EUR 30 million capital investment, described in press coverage as becoming a "reference shareholder." The exact percentage acquired by C2 Capital, and the remaining ownership split among the company’s founders and any other shareholders, was not disclosed in the sources reviewed. No itemised list of shareholders or shareholding percentages was located; the cached registry data available for this profile returns only a generic notice about Portuguese beneficial-ownership filing requirements rather than named holders.
Ultimate beneficial ownership
No verified ultimate beneficial owner has been identified for this entity from the sources reviewed. Not disclosed.
Data availability
Shareholder and UBO information for this entity is Partial: a single minority investor is publicly reported, but a full breakdown of shareholders, holdings and beneficial owners was not found in the sources reviewed as of September 2026.
Sources
- ECO / SRS Legal, "SRS Legal assessora investimento da C2 Capital na Bluepharma", https://eco.sapo.pt/2023/12/28/srs-legal-assessora-investimento-da-c2-capital-na-bluepharma/, published 28 December 2023, retrieved 23 September 2026.
- Bluepharma Group, investment announcement, https://www.bluepharmagroup.com/en/communication/media-center/bluepharma-industria-farmaceutica-reinforces-capital-through-an-investment-of-30-million-euros-from-c2-capital, retrieved 23 September 2026.
Officers
Directors and officers of Bluepharma – Industria Farmaceutica, S.A.
Public reporting confirms one verified, recent officer change for this entity. Effective January 2026, Sergio Simoes – a pharmacist, PhD in pharmaceutical sciences and Bluepharma co-founder – became CEO of BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A., succeeding co-founder Paulo Barradas Rebelo in that role. Barradas Rebelo, who previously served as President and CEO of the company, moved into the role of Chairman of Grupo Bluepharma, with a remit described in press coverage as strategic vision, innovation and the group’s future direction. A related executive change reported at the same time saw fellow co-founder Miguel Silvestre become CEO of the affiliated company Bluepharma Genericos – Comercio de Medicamentos, S.A. Nationality, country of residence, full occupation details and precise appointment/resignation dates for these individuals were not disclosed in the sources reviewed; only the effective month (January 2026) of the reported transition is confirmed.
Recent officer changes
- CEO appointment: Sergio Simoes appointed CEO of BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A., effective January 2026, succeeding Paulo Barradas Rebelo. Source: News Farma, October 2025.
- Role change: Paulo Barradas Rebelo moved from President/CEO of the company to Chairman of Grupo Bluepharma, effective January 2026. Source: News Farma / Diario de Coimbra, October 2025.
Data availability
Officer information for this entity is Partial: the most recent leadership transition is confirmed by reputable Portuguese trade and regional press, but a complete register of current and former directors, their appointment dates, nationalities and occupations was not accessible from the Portuguese commercial registry in the sources reviewed. A cached registry lookup for this entity’s directors and officers returned an access-limit error rather than data.
Sources
- News Farma, "Sergio Simoes e Miguel Silvestre assumem a lideranca executiva da Bluepharma Industria Farmaceutica e da Bluepharma Genericos", https://newsfarma.pt/atualidade/sergio-simoes-e-miguel-silvestre-assumem-a-lideranca-executiva-da-bluepharma-industria-farmaceutica-e-da-bluepharma-genericos/, retrieved 23 September 2026.
- Diario de Coimbra, "Sergio Simoes e Miguel Silvestre sao os CEO Bluepharma a partir de janeiro", https://www.diariocoimbra.pt/2025/10/20/sergio-simoes-e-miguel-silvestre-sao-os-ceo-bluepharma-a-partir-de-janeiro/, published 20 October 2025, retrieved 23 September 2026.
Group Structure
Group structure of Bluepharma – Industria Farmaceutica, S.A.
BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. is the pharmaceutical-manufacturing operating company of Grupo Bluepharma, a Portuguese pharmaceutical group whose own corporate communications describe it as comprising roughly 18 to 20 affiliated companies active across Portugal, Spain, Angola, Mozambique and the United States. The group’s own materials name a separate holding company, Bluepharma SGPS, S.A. (NIPC 505282950, registered at the same Coimbra address), and a separate commercial affiliate, Bluepharma Genericos – Comercio de Medicamentos, S.A. (NIPC 506037169). No official filing confirming the specific ownership percentages or the direct parent-subsidiary chain linking BLUEPHARMA – INDUSTRIA FARMACEUTICA, S.A. to Bluepharma SGPS, S.A. or to any other named group entity was located in the sources reviewed. These related companies are therefore described here as verified affiliates operating under the same group name and brand, not as a confirmed ownership chain.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Bluepharma SGPS, S.A. | Portugal | 505282950 | Affiliate (named group holding company; ownership chain not verified) | Ownership percentage not disclosed | Active | September 2026 |
| Bluepharma Genericos – Comercio de Medicamentos, S.A. | Portugal | 506037169 | Affiliate (same group; corporate link not verified by filing) | Ownership percentage not disclosed | Active | September 2026 |
Recent structural changes
No verified acquisitions, disposals, mergers or reorganisations affecting this specific legal entity were found in the sources reviewed. A December 2023 minority capital investment by C2 Capital was identified, but this is a shareholding event rather than a group-structure change and is addressed in the shareholders block.
Data availability
Group-structure information for this entity is Partial: the existence and names of affiliated group entities are publicly confirmed, but the underlying ownership filings needed to classify them as verified parents, subsidiaries or sister companies were not accessible in the sources reviewed. A cached registry lookup used as baseline for this profile returned no parent, subsidiary or ownership linkage for this entity.
Sources
- Bluepharma Group, "Company / Empresa", https://www.bluepharmagroup.com/pt/sobre-nos/empresa, retrieved 23 September 2026.
- Iberinform.pt, company profiles for NIF 505282801 and NIF 506037169, retrieved 23 September 2026.
- Racius.com company search index entries for Bluepharma – Industria Farmaceutica, S.A.; Bluepharma SGPS, S.A.; Bluepharma Genericos – Comercio de Medicamentos S.A., retrieved 23 September 2026.
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does Bluepharma do?
Portuguese pharmaceutical manufacturer (Sociedade Anonima, NIPC 505282801) based in Coimbra, active under CAE 21201 – Fabricacao de medicamentos; produces generic and branded solid-dose pharmaceuticals and was the first Portuguese manufacturer FDA-approved for US exports, in 2009.
Who owns Bluepharma?
Partial disclosure only: C2 Capital acquired a minority stake via a reported EUR 30 million investment in December 2023, described as a reference shareholder; full shareholder register and percentages not publicly disclosed.
Who is Bluepharma's UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) record is shown for Bluepharma, as public access to Portugal's RCBE beneficial-ownership register ended on 1 November 2025, and access now requires demonstrating a legitimate interest via digital ID login.
Is Bluepharma still an active company?
Bluepharma's status on Company Data Enrichment is listed as active.
When was Bluepharma incorporated?
Bluepharma was incorporated on 1 December 2000, according to Company Data Enrichment.
What is Bluepharma's registered address?
The registered address on file for Bluepharma is Ramsey, Portugal.
What is Bluepharma's revenue?
Reported annual revenue above EUR 50 million per Portuguese business-registry data (bracket estimate, filings on record for 2023-2025); 501-1,000 employees; share capital approximately EUR 5,244,940.
Is Bluepharma listed on a stock exchange?
Not listed on any stock exchange; privately held.
Who are the officers/directors of Bluepharma?
CEO Sergio Simoes, appointed January 2026, succeeding founder Paulo Barradas Rebelo, who became Chairman of Grupo Bluepharma; full director register not accessible in sources reviewed.
Does Bluepharma have a parent company or subsidiaries?
Operating manufacturing entity of Grupo Bluepharma; named affiliates include Bluepharma SGPS S.A. (NIPC 505282950) and Bluepharma Genericos – Comercio de Medicamentos S.A. (NIPC 506037169); direct ownership chain not verified by filing.
Can Zavia monitor changes to Bluepharma's ownership over time?
This profile reflects a point-in-time snapshot from Company Data Enrichment. Zavia's monitoring API can track changes to Bluepharma's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Bluepharma's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Portugal, so records like Bluepharma's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Company Data Enrichment and was last synced on 25 September 2026.